Challenges and new horizons in the management of advanced basal cell carcinoma

A UK perspective

J. T. Lear, C. Corner, Peter Dziewulski, K. Fife, G. L. Ross, S. Varma, C. A. Harwood

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Basal cell carcinoma (BCC) is a common malignancy with a good prognosis in the majority of cases. However, some BCC patients develop a more advanced disease that poses significant management challenges. Such cases include locally advanced, recurrent or metastatic BCC, or tumours that occur in anatomical sites where surgical treatment would result in significant deformity. Until recently, treatment options for these patients have been limited, but increased understanding of the molecular basis of BCC has enabled potential therapies, such as hedgehog signalling pathway inhibitors, to be developed. A clear definition of advanced BCC as a distinct disease entity and formal management guidelines have not previously been published, presumably because of the rarity, heterogeneity and lack of treatment options available for the disease. Here we provide a UK perspective from a multidisciplinary group of experts involved in the treatment of complex cases of BCC, addressing the key challenges associated with the perceived definition and management of the disease. With new treatments on the horizon, we further propose a definition for advanced BCC that may be used as a guide for healthcare professionals involved in disease diagnosis and management.

Original languageEnglish (US)
Pages (from-to)1476-1481
Number of pages6
JournalBritish Journal of Cancer
Volume111
Issue number8
DOIs
StatePublished - Oct 14 2014
Externally publishedYes

Fingerprint

Basal Cell Carcinoma
Disease Management
Therapeutics
Neoplasms
Guidelines
Delivery of Health Care

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Challenges and new horizons in the management of advanced basal cell carcinoma : A UK perspective. / Lear, J. T.; Corner, C.; Dziewulski, Peter; Fife, K.; Ross, G. L.; Varma, S.; Harwood, C. A.

In: British Journal of Cancer, Vol. 111, No. 8, 14.10.2014, p. 1476-1481.

Research output: Contribution to journalReview article

Lear, J. T. ; Corner, C. ; Dziewulski, Peter ; Fife, K. ; Ross, G. L. ; Varma, S. ; Harwood, C. A. / Challenges and new horizons in the management of advanced basal cell carcinoma : A UK perspective. In: British Journal of Cancer. 2014 ; Vol. 111, No. 8. pp. 1476-1481.
@article{e712892b67eb4a828ee9c1cb61a5aa24,
title = "Challenges and new horizons in the management of advanced basal cell carcinoma: A UK perspective",
abstract = "Basal cell carcinoma (BCC) is a common malignancy with a good prognosis in the majority of cases. However, some BCC patients develop a more advanced disease that poses significant management challenges. Such cases include locally advanced, recurrent or metastatic BCC, or tumours that occur in anatomical sites where surgical treatment would result in significant deformity. Until recently, treatment options for these patients have been limited, but increased understanding of the molecular basis of BCC has enabled potential therapies, such as hedgehog signalling pathway inhibitors, to be developed. A clear definition of advanced BCC as a distinct disease entity and formal management guidelines have not previously been published, presumably because of the rarity, heterogeneity and lack of treatment options available for the disease. Here we provide a UK perspective from a multidisciplinary group of experts involved in the treatment of complex cases of BCC, addressing the key challenges associated with the perceived definition and management of the disease. With new treatments on the horizon, we further propose a definition for advanced BCC that may be used as a guide for healthcare professionals involved in disease diagnosis and management.",
author = "Lear, {J. T.} and C. Corner and Peter Dziewulski and K. Fife and Ross, {G. L.} and S. Varma and Harwood, {C. A.}",
year = "2014",
month = "10",
day = "14",
doi = "10.1038/bjc.2014.270",
language = "English (US)",
volume = "111",
pages = "1476--1481",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Challenges and new horizons in the management of advanced basal cell carcinoma

T2 - A UK perspective

AU - Lear, J. T.

AU - Corner, C.

AU - Dziewulski, Peter

AU - Fife, K.

AU - Ross, G. L.

AU - Varma, S.

AU - Harwood, C. A.

PY - 2014/10/14

Y1 - 2014/10/14

N2 - Basal cell carcinoma (BCC) is a common malignancy with a good prognosis in the majority of cases. However, some BCC patients develop a more advanced disease that poses significant management challenges. Such cases include locally advanced, recurrent or metastatic BCC, or tumours that occur in anatomical sites where surgical treatment would result in significant deformity. Until recently, treatment options for these patients have been limited, but increased understanding of the molecular basis of BCC has enabled potential therapies, such as hedgehog signalling pathway inhibitors, to be developed. A clear definition of advanced BCC as a distinct disease entity and formal management guidelines have not previously been published, presumably because of the rarity, heterogeneity and lack of treatment options available for the disease. Here we provide a UK perspective from a multidisciplinary group of experts involved in the treatment of complex cases of BCC, addressing the key challenges associated with the perceived definition and management of the disease. With new treatments on the horizon, we further propose a definition for advanced BCC that may be used as a guide for healthcare professionals involved in disease diagnosis and management.

AB - Basal cell carcinoma (BCC) is a common malignancy with a good prognosis in the majority of cases. However, some BCC patients develop a more advanced disease that poses significant management challenges. Such cases include locally advanced, recurrent or metastatic BCC, or tumours that occur in anatomical sites where surgical treatment would result in significant deformity. Until recently, treatment options for these patients have been limited, but increased understanding of the molecular basis of BCC has enabled potential therapies, such as hedgehog signalling pathway inhibitors, to be developed. A clear definition of advanced BCC as a distinct disease entity and formal management guidelines have not previously been published, presumably because of the rarity, heterogeneity and lack of treatment options available for the disease. Here we provide a UK perspective from a multidisciplinary group of experts involved in the treatment of complex cases of BCC, addressing the key challenges associated with the perceived definition and management of the disease. With new treatments on the horizon, we further propose a definition for advanced BCC that may be used as a guide for healthcare professionals involved in disease diagnosis and management.

UR - http://www.scopus.com/inward/record.url?scp=84908892950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908892950&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.270

DO - 10.1038/bjc.2014.270

M3 - Review article

VL - 111

SP - 1476

EP - 1481

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -